The FDA has approved Rasonque (daraxonrasib) — the first targeted therapy to strike at RAS, the central cancer-driving pathway in pancreatic cancer — a landmark in one of the deadliest and hardest-to-treat cancers.
Cleared August 26, 2026, the once-daily drug from Revolution Medicines is approved for adults with metastatic pancreatic adenocarcinoma who have had at least one prior systemic therapy or who aren’t candidates for multi-drug chemotherapy. Its significance is biological: more than 90% of pancreatic cancers carry mutations in the KRAS oncogene, part of the RAS family — long considered “undruggable.”
The survival data
In a randomized, open-label trial of 500 adults with previously treated metastatic pancreatic cancer, Rasonque improved median overall survival to 13.2 months, versus 6.7 months for standard chemotherapy — nearly doubling it. The FDA granted the drug Breakthrough Therapy and Orphan Drug designations and Priority Review, and reviewed it through a national-priority pilot program meant to speed high-impact treatments.
Why it matters
Pancreatic cancer has among the worst survival of any major cancer, and treatment options have barely changed in years. A drug that targets the disease’s core driver — and extends life — is a genuine milestone, and it validates a broader effort to finally make RAS druggable across many cancer types.